We identified NEFL as a novel target of miR-381 that was apparently downregulated in GBM, and we showed that inhibition of miR-381 enhanced the sensitivity of NEFL-mediated stemness factors to TMZ in GBM. The gene discussed is NEFL; the disease is glioblastoma.